Logo

Merck and Daiichi Sankyo Report the Initiation of P-III (IDeate-Lung02) Study of Ifinatamab Deruxtecan to Treat Small Cell Lung Cancer

Share this

Merck and Daiichi Sankyo Report the Initiation of P-III (IDeate-Lung02) Study of Ifinatamab Deruxtecan to Treat Small Cell Lung Cancer

Shots:

  • The companies have dosed the first patient in the P-III (IDeate-Lung02) trial assessing the safety & efficacy of ifinatamab deruxtecan (12mg/kg) vs CT (amrubicin, lurbinectedin or topotecan) to treat relapsed SCLC patients (n=~460) in Asia, EU, Oceania, North & South America
  • The dual 1EPs include ORR (evaluated by BICR) & OS while the 2EPs are ORR (evaluated by the investigator) as well as PFS, DoR, DCR & time to response (investigated by both BICR & investigator)
  • The updated subgroup analysis from P-I/II (IDeate-PanTumor01) study (highlighted at the WCLC 2023) of ifinatamab deruxtecan formed the basis of this study

Ref: Merck | Image: Merck & Daiichi Sankyo

Related News:- Merck Reports the CHMP’s Positive Opinion of Keytruda Plus Padcev to Treat Unresectable or Metastatic Urothelial Carcinoma

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions